Cambridge Healthtech Institute’s Third Annual

Adoptive T-Cell Therapy

Success from Bench to Bedside with Improved Approaches

19-20 March 2018 | Hilton London Canary Wharf | London

 

We will present several different approaches focusing on their limitations and strengths, and how specificity is optimized while off-site toxicity is avoided. We will examine developments for attacking solid tumours, and their potential for non-personalized therapies, together with efforts to automate and simplify. We will present data from bench to bedside including preclinical models, translational studies and successes in the clinic.

I am looking for case studies on the following:

  1. CAR-T Cells: Modes of action; improved methodologies; enhancement of specificity and efficacy; management of off-site toxicity; correlates and translational studies; developments with solid tumours.
  1. T-Cell Receptors (TCRs): Comparison with other approaches; optimization and safety studies; overcoming off-target tox; potential for targeting solid tumours.
  1. Tumour Infiltrating Lymphocytes (TILS): How the industry can benefit from TILs; enhancement of potency, monitoring of efficacy, tox concerns, potential for non-personalized therapy and for combining with other approaches.
  1. Exploiting Innate Immune Cells for Adoptive T Cell Therapy
  1. Next Generation of CAR-T Cells: Impact on cytokine release.
  1. Genetic Engineering of CAR-T Cells
  1. Preclinical Models: Choice and design of preclinical models; advantages and limitations; predictability of chosen model; results that are convincing and can justify the clinical trial.
  1. Experiences with T-Cell Product Manufacturing: The challenges and ways of overcoming them; avoidance of cross-contamination, developments with automation, regulatory considerations.
  1. Preclinical, Translational and Clinical Experiences: Correlative studies; design, application and approval of the clinical trial.
  1. Biomarker Discovery for Adoptive T Cell Therapies
  1. Selection of Target Antigens
  1. Developments regarding Solid Tumours
  1. Developments with Off-the-Shelf Approaches

If you would like to submit a proposal to give a presentation at this meeting, please click here.     

Deadline for submission is 8 September 2017

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference programme. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
+44 7791 866489
nlyscom@healthtech.com 

For sponsorship and exhibit information, please contact: 
Companies A-K
Jason Gerardi
Senior Manager, Business Development
+1 781-972-5452
jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Senior Manager, Business Development
Cambridge Healthtech Institute
+1 781-972-5471
dinerstein@healthtech.com